{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-003807","form_type":"8-K","ticker":"GANX","cik":"0001819411","company_name":"Gain Therapeutics, Inc.","filed_at":"2025-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.050717+00:00","generated_at":"2026-05-24T04:13:05.425069+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Gain Therapeutics reports FY2024 net loss $20.4M; Phase 1b dosing initiated for GT-02287","bullets":["Net loss of $20.4M ($0.89 EPS) vs $22.3M ($1.71 EPS) in FY2023; revenue not reported.","Cash and securities $10.4M at Dec 31, 2024, down from $16.8M a year earlier.","First patient dosed in Phase 1b trial of GT-02287 for Parkinson's disease; first analysis expected Q2 2025.","Gene Mack appointed President and CEO effective Jan 6, 2025; pre-IND engagement with FDA started.","R&D expenses fell to $10.8M and G&A to $9.6M vs $11.5M and $10.8M in FY2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-003807","json":"https://secwatch.observer/filing/0001558370-25-003807.json","markdown":"https://secwatch.observer/filing/0001558370-25-003807.md","text":"https://secwatch.observer/filing/0001558370-25-003807.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819411/000155837025003807/0001558370-25-003807-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819411/000155837025003807/ganx-20250327x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T04:13:05.425069+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}